Securities & Capital Markets
Viewpoints
Filter by:
California Board Diversity Statute Unconstitutional
April 12, 2022 | Alert | By Kevin M. Yao, Melanie Ruthrauff Levy
This article discusses the LA Superior Court’s April 1, 2022 ruling in Crest v. Padilla, which challenged the constitutionality of a California statute requiring certain publicly traded companies to include members from underrepresented communities on their boards.
Webinar Recording: A Closer Look at the SEC's Proposed Climate-Related Disclosures and Implications for Public Companies
April 6, 2022 | Webinar | By Megan Gates, Jacob Hupart, William F. Weld
In this webinar, former Massachusetts Governor Bill Weld, and Members Megan Gates and Jacob Hupart, examine key takeaways from the SEC’s proposed climate-related disclosures rule.
A Brief Summary of the SEC’s Proposed Climate-Related Rules
March 30, 2022 | Advisory | By Jacob Hupart, Megan Gates, William F. Weld, Doug Baumstein, Jennifer Rubin
This alert outlines key aspects of the SEC’s new proposed rules on climate disclosures, entitled “The Enhancement and Standardization of Climate-Related Disclosures for Investors.”
SEC Proposes New Cybersecurity Rules for Public Companies
March 21, 2022 | Advisory | By Roman M. Gorokhov, Cynthia Larose, Megan Gates, John Condon
This advisory outlines the SEC’s new proposed cybersecurity disclosure rules and discusses how the changes will impact public companies and their boards.
Financing Options for Life Sciences Companies in 2022
March 21, 2022 | Blog
Public and private life science companies have multiple options available for capital-raising. Here are a few to be considered.
Preparation for 2021 Fiscal Year-End SEC Filings and 2022 Annual Shareholder Meetings
January 18, 2022 | Advisory | By Megan Gates, John Condon, Anne Bruno, Melanie Ruthrauff Levy, Daniel T. Kajunski, Cynthia Larose, Breton Leone-Quick, Page R. Hubben
Spotlight on ESG Investing: The Importance of Understanding Environmental, Social and Governance Factors and Their Impact on Investing
October 19, 2021 | Article | By Jonathan L. Kravetz
Massachusetts Executive Order Permitting Massachusetts Public Companies to Hold Virtual-Only Shareholder Meetings to Expire
July 12, 2021 | Advisory | By Anne Bruno
The Public Weighs In On How the SEC Should Regulate ESG Disclosures
June 22, 2021 | Blog | By Jacob Hupart, Ellen Shapiro
NYSE Amends Related Party Transaction Approval Rule
May 27, 2021 | Advisory | By Daniel T. Kajunski
NYSE Amends Shareholder Approval Rules
May 26, 2021 | Advisory | By Daniel T. Kajunski
Not So Fast: DOL Changes Course on Trump-Era ESG Investment Rule
March 22, 2021 | Blog | By Alyssa C. Scruggs
The OASB Annual Report to Congress for Fiscal Year 2020
March 15, 2021 | Blog | By Amanda Mei
SPAC Chat: Busting Common Myths about SPACs
February 9, 2021 | Podcast | By Thomas Burton, Jeffrey Schultz, Sahir Surmeli
SEC Amends MD&A and Other Financial Disclosure Rules
February 5, 2021 | Alert | By Daniel T. Kajunski, Amanda Mei
Preparation for 2020 Fiscal Year-End SEC Filings and 2021 Annual Shareholder Meetings
January 21, 2021 | Advisory | By Megan Gates, John Condon, Daniel T. Kajunski, Anne Bruno
How Companies Can Prepare for SEC Proxy Advisor Reform
January 12, 2021 | Advisory | By Anne Bruno
SEC Adopts Rules to Allow the Use of Electronic Signatures
November 19, 2020 | Alert | By Daniel T. Kajunski
SEC Harmonizes and Improves “Patchwork” Private Offering Framework
November 12, 2020 | Alert
Explore Other Viewpoints:
- Data Centers & Digital Infrastructure
- AI: The Washington Report
- Antitrust and Federal Regulation
- Appellate
- Arbitration, Mediation & Alternate Dispute Resolution
- Artificial Intelligence
- Awards
- Bankruptcy & Restructuring
- California Land Use
- Cannabis
- Class Action
- Complex Commercial Litigation
- Construction
- Consumer Product Safety
- Consumer Protection Defense
- Corporate Governance (ESG)
- Crisis Management and Strategic Response
- Cross-Border Asset Recovery
- DEI Legal Developments
- Debt Financing
- Direct Investing (M&A)
- Diversity
- EB-5 Financing
- Education & Nonprofits
- Employment
- EnforceMintz
- Environmental (ESG)
- Environmental Enforcement Defense
- Environmental Law
- Environmental, Social, and Corporate Governance (ESG)
- FDA Regulatory
- FDA in Flux
- False Claims Act
- Federal Circuit Appeals
- Financial Institution Litigation
- Government Law
- Growth Equity
- Health Care
- Health Care Compliance, Fraud and Abuse, & Regulatory Counseling
- Health Care Enforcement & Investigations
- Health Care Transactions
- Health Information Privacy & Security
- IP Due Diligence
- IPRs & Other Post Grant Proceedings
- Immigration
- Impacts of a New US Administration
- Inside Digital Infrastructure
- Insolvency & Creditor Rights Litigation
- Institutional Investor Class Action Recovery
- Insurance & Financial Services
- Insurance Consulting & Risk Management
- Insurance and Reinsurance Problem-Solving & Dispute Resolution
- Intellectual Property
- Investment Funds
- Israel
- Licensing & Technology Transactions
- Life Sciences
- Litigation & Investigations
- M&A Litigation
- ML Strategies
- Managed Care
- Medicare, Medicaid and Commercial Coverage & Reimbursement
- Mergers & Acquisitions
- Patent Litigation
- Patent Prosecution & Strategic Counseling
- Pharmacy Benefits and PBM Contracting
- Portfolio Companies
- Privacy & Cybersecurity
- Private Client
- Private Equity
- Pro Bono
- Probate & Fiduciary Litigation
- Products Liability & Complex Tort
- Projects & Infrastructure
- Public Finance
- Real Estate Litigation
- Real Estate Litigation, Construction & Infrastructure
- Real Estate Transactions
- Retail & Consumer Products
- Securities & Capital Markets
- Securities Litigation
- Social (ESG)
- Special Purpose Acquisition Company (SPACs)
- Sports & Entertainment
- State Attorneys General
- Strategic IP Monetization & Licensing
- Sustainable Energy & Infrastructure
- Tax
- Technology
- Technology, Communications & Media
- Technology, Communications & Media Litigation
- Trade Secrets
- Trademark & Copyright
- Trademark Litigation
- Unified Patent Court (UPC)
- Value-Based Care
- Venture Capital & Emerging Companies
- White Collar Defense & Government Investigations
- Women's Health and Technology






